Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CING
$6.34
$
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Next Earnings
2026-02-25
Beta
-0.752
Average Volume
Market Cap
Last Dividend
CIK
0001862150
ISIN
US17248W3034
CUSIP
17248W105
CEO
Shane J. Schaffer
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
13
IPO Date
2021-12-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts | Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price | Defense World | 2025-12-26 02:38:48 |
| Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts | Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price | Defense World | 2025-12-26 02:38:46 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| PRE 14A | 2026-02-18 | 2026-02-18 | View Filing |
| 8-K | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| SC 13D | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-06 | 2026-02-06 | View Filing |
| 8-K | 2026-01-28 | 2026-01-28 | View Filing |
| 8-K | 2026-01-15 | 2026-01-15 | View Filing |
| S-3 | 2026-01-12 | 2026-01-12 | View Filing |
| 424B5 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 8-K | 2026-01-02 | 2026-01-02 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| 3 | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| 8-K | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 10-Q | 2025-08-19 | 2025-08-19 | View Filing |
| 8-K | 2025-08-19 | 2025-08-19 | View Filing |
| DEF 14A | 2025-08-15 | 2025-08-15 | View Filing |
| NT 10-Q | 2025-08-15 | 2025-08-15 | View Filing |
| 8-K | 2025-08-15 | 2025-08-15 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| PRE 14A | 2025-08-05 | 2025-08-05 | View Filing |
| 424B3 | 2025-07-30 | 2025-07-30 | View Filing |
| EFFECT | 2025-07-30 | 2025-07-30 | View Filing |
| S-8 | 2025-07-25 | 2025-07-25 | View Filing |
| S-1/A | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-25 | 2025-07-25 | View Filing |
| S-1 | 2025-07-22 | 2025-07-22 | View Filing |
| 8-K | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 3 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 4 | 2025-07-09 | 2025-07-09 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| PRE 14A | 2025-04-15 | 2025-04-15 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-10-15 | 2024-10-15 | View Filing |
| 424B5 | 2024-10-15 | 2024-10-15 | View Filing |
| EFFECT | 2024-10-08 | 2024-10-08 | View Filing |
| 424B3 | 2024-10-07 | 2024-10-07 | View Filing |
| S-1/A | 2024-10-07 | 2024-10-07 | View Filing |
| 8-K | 2024-10-07 | 2024-10-07 | View Filing |
| 8-K | 2024-10-04 | 2024-10-04 | View Filing |
| S-1/A | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-10-01 | 2024-10-01 | View Filing |
| 4 | 2024-10-01 | 2024-10-01 | View Filing |
| S-1 | 2024-09-27 | 2024-09-27 | View Filing |
| 8-K | 2024-09-12 | 2024-09-12 | View Filing |
| 8-K | 2024-09-10 | 2024-09-10 | View Filing |
| 424B5 | 2024-09-03 | 2024-09-03 | View Filing |
| 8-K | 2024-09-03 | 2024-09-03 | View Filing |
| SC 13D/A | 2024-08-30 | 2024-08-30 | View Filing |
| 8-K | 2024-08-29 | 2024-08-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Mean Reversion Strategy | 38.92% | 1.01 | 433 | 0.04 | 0.09 | 36.39 |
| Bollinger Bands Strategy | 36.69% | 0.99 | 79 | 0.05 | 0.13 | 34.17 |
| Williams PercentR Strategy | 33.83% | 1 | 316 | 0.04 | 0.08 | 31.3 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |